| Mepolizumab in eosinophilic disorders. | |
| | |
MedLine Citation:
|
PMID: 21790283 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Mepolizumab (Bosatria(®), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 κ type, which targets human IL-5 and thus prevents its interaction with the α-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders. |
| | |
Authors:
|
J Pablo Abonia; Philip E Putnam |
Related Documents
:
|
11317963 - Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycytha... 17015893 - 18f-flt pet in hematologic disorders: a novel technique to analyze the bone marrow comp... 7691773 - Etretinate therapy for psoriasis and other keratinizing disorders: a 10-year retrospect... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of clinical immunology Volume: 7 ISSN: 1744-8409 ISO Abbreviation: Expert Rev Clin Immunol Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-07-27 Completed Date: 2011-11-15 Revised Date: 2012-05-02 |
Medline Journal Info:
|
Nlm Unique ID: 101271248 Medline TA: Expert Rev Clin Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 411-7 Citation Subset: IM |
Affiliation:
|
Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML2010, Cincinnati, OH 45229-3039, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / pharmacology, therapeutic use* Antibodies, Monoclonal, Humanized Asthma / drug therapy*, immunology Churg-Strauss Syndrome / drug therapy*, immunology Clinical Trials as Topic Drug Evaluation, Preclinical Eosinophilia Eosinophils / drug effects*, immunology Humans Hypereosinophilic Syndrome / drug therapy*, immunology Interleukin-5 / immunology, metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
R01 DK076893-03S1/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/IL5 protein, human; 0/Interleukin-5; 0/mepolizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An Outbreak of Salmonella Typhimurium 108/170 at a Privately Catered Barbeque at a Sydney Sports Clu...
Next Document: Budesonide in the treatment of inflammatory bowel disease.